secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK:        0000875320
Form:       8-K
Filed at:   2026-05-04T23:59:59+00:00
Accession:  0000875320-26-000171
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vertex Q1 revenue $2.99B (+8% YoY); reiterates FY2026 guidance; povetacicept BLA submitted for accelerated approval
--------------------------------------------------------------------------------

- Total revenue $2.99B, up 8% vs Q1 2025; GAAP net income $1.0B, non-GAAP $1.1B.
- CASGEVY revenue $43M; JOURNAVX revenue $29M; non-CF products drove >25% of growth.
- Completed rolling BLA submission for povetacicept in IgAN for U.S. accelerated approval; Priority Review Voucher expected to expedite review to 6 months.
- Terminated VX-522 (CF) Phase 1/2 due to persistent tolerability issues; no efficacy readout possible.
- FY2026 guidance reiterated: revenue $12.95-13.1B, combined R&D/SG&A unchanged.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875320/000087532026000171/0000875320-26-000171-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875320/000087532026000171/vrtx-20260504.htm
  HTML page:      https://secwatch.observer/filing/0000875320-26-000171

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer